---
title: "Junshi Biosciences Discloses Equity Reduction by Major Shareholder Group"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289792282.md"
description: "Shanghai Junshi Biosciences (HK:1877) announced that major shareholder Shanghai Tanying Investment Partnership and its concerted parties reduced their stake from 7.91% to 6.94%. The holding remains above the 5% threshold, and the reduction does not breach commitments or trigger tender offer obligations. The board described this as a routine adjustment with no change in control. Analysts maintain a 'Hold' rating with a HK$34.70 price target."
datetime: "2026-06-15T13:20:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289792282.md)
  - [en](https://longbridge.com/en/news/289792282.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289792282.md)
generator: "portal-rs"
---

# Junshi Biosciences Discloses Equity Reduction by Major Shareholder Group

An update from Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) is now available.

Shanghai Junshi Biosciences Co., Ltd. announced changes in the shareholding of major investor Shanghai Tanying Investment Partnership (LP) and its concerted parties, which collectively reduced their equity stake in the company. Following the transactions, their combined holding fell from 7.91% to 6.94% of the company’s shares, remaining above the 5% major shareholder threshold.

The company confirmed that the reduction in shareholding does not breach any existing commitments, intentions or plans previously disclosed by these investors and does not trigger a mandatory tender offer obligation. The board stated that the disclosure is consistent with information provided by the shareholders, signaling a routine adjustment of holdings rather than a change in control or strategic direction.

The most recent analyst rating on (HK:1877) stock is a Hold  
 with a HK$34.70 price target.  
 To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock,  
 see the HK:1877 Stock Forecast page. 

**More about Shanghai Junshi Biosciences Co., Ltd. Class H**

Shanghai Junshi Biosciences Co., Ltd. is a PRC-incorporated biopharmaceutical company listed in Hong Kong and Shanghai, active in innovative drug research and development. The company operates in the biotechnology and life sciences sector, with a diversified shareholder base that includes institutional investors holding significant equity stakes.

**Average Trading Volume:** 4,361,083

**Technical Sentiment Signal:** Sell

**Current Market Cap:** HK$31.69B

For an in-depth examination of 1877 stock, go to TipRanks’ Overview page.

### Related Stocks

- [688180.CN](https://longbridge.com/en/quote/688180.CN.md)
- [01877.HK](https://longbridge.com/en/quote/01877.HK.md)

## Related News & Research

- [Junshi Biosciences Shareholders Approve H-Share Buyback Mandate](https://longbridge.com/en/news/293923779.md)
- [Junshi Biosciences Completes RMB300 Million Technology Innovation Bond Issuance](https://longbridge.com/en/news/293479960.md)
- [Canadian Life Companies Split declares monthly distribution of $0.1 per Class A share and $0.06 per preferred share](https://longbridge.com/en/news/296359920.md)
- [Klappir publishes investor presentation for Class B share offering at EUR 3.43 per share](https://longbridge.com/en/news/296407110.md)
- [Canadian Banc declares monthly distribution of $0.22 per Class A share, $0.05 per preferred share](https://longbridge.com/en/news/296359735.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**